Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Syndax Pharmaceuticals (SNDX) Stock Up 4.79% Today?

Why Is Syndax Pharmaceuticals (SNDX) Stock Up 4.79% Today?

Key Takeaways

  • Shares of SNDX rose 4.79%, or $0.41, to $8.97 in midday trading, up from Wednesday's close of $8.56.
  • No company press release, SEC filing, analyst action, or wire report explains the size of the move; the catalyst appears technical rather than fundamental.
  • The stock is bouncing from a fresh 52-week low of $8.47 hit on November 18, when it fell nearly 7% and closed deeply oversold.
  • Secondary driver: management's scheduled fireside chat at the Jefferies London Healthcare Conference earlier this morning drew fresh attention to a heavily discounted valuation.
  • Context remains bearish: a failed Phase 2 pulmonary fibrosis study in October and a Q3 earnings miss on November 2 have cut the share price by more than half year to date, leaving a market value near $810 million.
  • News Significance Score: 19/100 — routine and largely absent news paired with a move only about 1.6 times the stock's typical daily swing.
  • Traders are watching December's ASH hematology meeting, fourth-quarter publication of NUP98-rearranged leukemia data, and any update on the path to profitability.
  • Deeper research on SNDX is available through dedicated pages covering Price Targets, Earnings, and Forecast.
  • Readers can also explore Trending AI Robots for automated strategies currently outperforming in this market.

Opening Summary

Syndax Pharmaceuticals (SNDX) is a commercial-stage biopharmaceutical company based in New York that sells two FDA-approved cancer therapies: Revuforj, a menin inhibitor for acute leukemias, and Niktimvo, an antibody for chronic graft-versus-host disease developed with Incyte. In trading on Thursday, the stock gained 4.79% to $8.97, compared with the prior session's close of $8.56, confirming an upward move of $0.41 per share. No verified news catalyst was found for the advance; the session instead looks consistent with an oversold rebound following the stock's slide to a 52-week low a day earlier.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found in company disclosures, filings, or market reporting accounts for Thursday's gain. Syndax issued no press release, disclosed no new clinical data, and drew no analyst rating change or price target revision. The only scheduled corporate event was a fireside chat at the Jefferies London Healthcare Conference at 7:30 a.m. Eastern — a routine investor appearance that precedes the open rather than a disclosure event, though management commentary at such meetings can nudge sentiment in a thinly traded, heavily shorted name.

The more probable explanation is technical. The stock bottomed at $8.47 on Wednesday, a new 52-week low, and had fallen roughly 37% in the prior month. That left the shares deeply stretched below their 50-day and 200-day moving averages, near $14.60 and $19.50 respectively, with a 14-day relative strength index in the low 20s — a reading that often precedes short-lived mean-reversion rallies. With the stock down more than 50% year to date, sellers are less numerous and modest buying can move the tape meaningfully, particularly in a name with roughly 81 million freely tradable shares.

The Backdrop: A Brutal Six Weeks

Thursday's bounce does little to alter a damaged narrative. On October 13, the shares fell about 16% after a Phase 2 study of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint, prompting Syndax to abandon development in that indication. On November 2, the company reported third-quarter revenue of $83.3 million, up 82% year over year, with Revuforj net revenue of $60.7 million and Niktimvo net sales of $67.4 million. Revenue beat estimates, but a wider-than-expected adjusted loss of $0.55 per share, combined with the pipeline setback and the departure of the chief financial officer, triggered a 26.9% drop on November 4 and a further 10.3% decline the next day. Subsequent law-firm inquiries into the fibrosis program added an overhang. Any rally from here starts from a valuation that already assumes considerable execution risk.

Market Context and Trading Activity

Activity has been unusually heavy throughout the decline. Wednesday's session traded about 3.47 million shares against a three-month average near 2.5 million, and intraday amplitude exceeded 10%. Volatility of that scale tends to persist for several sessions rather than resolve in one, which is consistent with Thursday's rebound being part of a bottoming attempt rather than a clean reversal.

The advance looks idiosyncratic rather than sector-driven: it follows a company-specific selloff and a company-specific low, with no fresh industry catalyst behind it. Technically, the shares remain far below every major moving average, so the session represents a bounce inside a downtrend, not a trend change. The first meaningful resistance sits near the $9.40 level that capped Wednesday's rally attempt, with the prior earnings gap around $10.45 above that. Support is defined by Wednesday's $8.47 low.

News Significance Score

The score runs from 0 to 100, where 0 means no meaningful news and a move in line with the stock's normal behavior, and 100 means transformative news paired with a rare, extreme price move. Syndax scores 19 out of 100.

Verified news was minimal: no release, filing, or analyst action accompanied the gain, and the sole scheduled event — an investor conference chat — carries little weight for a company of this size. The price move was also ordinary by the stock's own standards, roughly 1.6 times a typical daily swing of about 2.9%, and exceeded or matched eight times in the past 60 sessions. Weak news plus a routine move produces a low score.

What Comes Next for SNDX

Attention turns to December's American Society of Hematology annual meeting, where Syndax plans to present new Revuforj data across multiple trials and real-world studies, including front-line combination results. The company also expects to publish data in relapsed or refractory NUP98-rearranged acute leukemia during the fourth quarter, a publication that could support guideline inclusion. Beyond that, Niktimvo combination data in chronic graft-versus-host disease are expected in the first quarter of 2027, alongside the start of the MenTain maintenance trial.

Financially, Syndax ended the third quarter with $551 million in cash and guided 2026 research, development, selling, general and administrative expense to roughly $400 million, excluding stock compensation. Investors will scrutinize the pace of Revuforj growth as transplant pauses weigh on near-term revenue, competitive menin inhibitor launches, and the credibility of management's path to profitability. The next quarterly report is expected in late February 2027. Risks include further pipeline disappointments, reimbursement pressure, and continued legal scrutiny of the fibrosis program.

Trending AI Robots

Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and traded symbols, allowing investors to compare approaches side by side. Amid swings like those in SNDX, reviewing how automated strategies are positioned can add a useful layer of perspective to your research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SNDX

SNDX's Indicator enters downward trend

The Aroon Indicator for SNDX entered a downward trend on November 17, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 208 similar instances where the Aroon Indicator formed such a pattern. In 169 of the 208 cases the stock moved lower. This puts the odds of a downward move at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDX as a result. In 72 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.

The Moving Average Convergence Divergence Histogram (MACD) for SNDX turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 31 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in 220 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. SNDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (56.421) is normal, around the industry mean (3.592). P/E Ratio (-3.801) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (6.010) is also within normal values, averaging (442.120).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals for novel cancer therapies

Industry Biotechnology

Industry
Biotechnology
Address
730 Third Avenue
Phone
+1 781 419-1400
Employees
277
Web
https://www.syndax.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.